ZymoGenetics: Clinical Trials

4 trials sponsored by ZymoGenetics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Phase 21Completed 1

Follow ZymoGenetics: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
PEGylated recombinant interleukin 29 (PEG-rIL-29) - Hepatitis C, Chronic
Phase 1CompletedZymoGenetics562007-12-012009-10-07
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
rIL-21 only, rIL-21 + sorafenib - Carcinoma, Renal Cell
Phase 1 / Phase 2CompletedZymoGenetics522006-10-012009-05-27
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
recombinant human interleukin 21 and rituximab - Lymphoma, Non-Hodgkin
Phase 1CompletedZymoGenetics232006-06-012008-09-05
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Recombinant Human Interleukin-21 - Melanoma, Kidney Neoplasms
Phase 1CompletedZymoGenetics432004-05-012009-03-09

Conditions studied

Carcinoma, Renal Cell (2)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Infections (1)  ·  Kidney Neoplasms (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)  ·  Virus Diseases (1)

Interventions

Rituximab (1)  ·  Sorafenib (1)  ·  peginterferon lambda-1a (1)

Countries

United States (4)  ·  Canada (1)

Top investigators

Diana F Hausman, MD (1)  ·  Diana Hausman, MD (1)  ·  Muriel Siadak, PA-C (1)  ·  Naomi Hunder, MD (1)

Results publications

PMID 24829759